Australian biotech, Trimph, has successfully completed a first-in-human trial of its proprietary bone “glue”, TrimphDent, the only bone graft substitute in the world to be applied in liquid form, halving the time of patient recovery, and requiring no specialised preparation or additional surgical expertise.
This breakthrough will allow Trimph to progress towards registering TrimphDent and launching into global markets, which could provide significantly more affordable and accessible oral surgeries to rural and disadvantaged communities across the globe.
{iframe}http://anthillonline.com/australian-biotech-startup-produced-world-first-bone-glue-secured-3-4-million-funding/{/iframe}